呼吸系统疾病疫苗市场、机会、成长动力、产业趋势分析与预测，2024-2032

在呼吸道疾病发生率增加和疫苗技术显着进步的推动下，2024年至2032年全球呼吸道疾病疫苗市场复合年增长率将达到4.1%。流感、COVID-19 和呼吸道合胞病毒(RSV) 等呼吸道疾病的激增，提高了对有效疫苗的需求。提供新药审批量的增加也支持了这一需求，例如，2024 年7 月，英国製药公司葛兰素史克(GSK) 开发的预防呼吸道合胞病毒(RSV) 的疫苗Arexvy 获得了健康科学局的批准。

技术创新，特别是 mRNA 技术，正在彻底改变疫苗的开发，从而能够快速有效地应对新出现的呼吸道威胁。此外，公众意识的提高和政府促进疫苗接种的措施也有助于呼吸道疾病疫苗市场的扩大。

整个呼吸道疾病疫苗产业根据技术、年龄层、感染、配销通路和地区进行分类。

mRNA技术将在呼吸道疾病疫苗市场的成长中发挥关键作用。 mRNA 疫苗在应对 COVID-19 方面的成功证明了其快速开发和高效的潜力。这项技术能够製造出能够迅速适应新的呼吸道病毒株的疫苗，从而对新出现的威胁做出灵活、及时的反应。 mRNA 疫苗的工作原理是指导细胞产生触发免疫反应的蛋白质，从而提供对特定病原体的保护。 mRNA 技术的可扩展性、速度和精确度将推动呼吸道疾病疫苗的重大进步，满足对有效和适应性解决方案不断增长的需求。

儿科细分市场将在呼吸系统疾病疫苗市场中占据显着份额。儿童的疫苗接种计划对于控制呼吸道疾病的传播和保护弱势群体至关重要。随着人们对幼儿免疫接种的日益关注以及儿童呼吸道感染盛行率的上升，专门针对该年龄层设计的疫苗的需求不断增长。正在开发儿童疫苗以应对一系列呼吸道疾病，包括流感和 RSV，重点是安全性、有效性和易于给药。此细分市场的成长是由于保护儿童免受严重呼吸道疾病和减轻医疗系统负担的需要所推动的。

2024年至2032年，欧洲呼吸道疾病疫苗市场将大幅成长。在强而有力的监管框架和政府措施的支持下，欧洲国家正在投资先进的疫苗研发。对公共卫生运动和疫苗接种计划的重视进一步推动了市场扩张。此外，欧洲人口的多样化和呼吸道疾病的高盛行率对创新疫苗解决方案产生了巨大需求，从而促进了该地区市场的整体成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 呼吸道疾病盛行率增加
    • 流感、肺炎、百日咳和呼吸道合胞病毒（RSV）等疾病负担不断增加
    • 不断进步的技术进步
    • 医疗保健支出不断增长
  • 产业陷阱与挑战
    • 由于病原体不断进化、费用增加和开发时间延长，疫苗开发变得复杂
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 差距分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 病毒载体
• 信使RNA
• 共轭
• 活衰减
• 灭活
• 重组
• 其他技术

第 6 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 儿科
• 成人

第 7 章：市场估计与预测：按感染情况分类，2021 - 2032 年

• 主要趋势
• 新冠肺炎
• 流感
• 呼吸道合胞病毒（RSV）
• 肺炎
• 其他感染

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 其他分销管道

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AstraZeneca
• Emergent BioSolutions Inc.
• GSK plc.
• Johnson and Johnson Services, Inc.
• Merck and Co., Inc.
• Novavax
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• SINOVAC

Global Respiratory Disease Vaccine Market will witness a 4.1% CAGR from 2024 to 2032, driven by increasing respiratory disease incidences and significant advancements in vaccine technology. The surge in respiratory conditions, such as influenza, COVID-19, and respiratory syncytial virus (RSV, is raising the demand for effective vaccines. The emergence of new respiratory pathogens and the ongoing threat of pandemics have heightened the need for advanced vaccines that offer robust protection. Rising approvals of new medications also support the demand. For instance, in July 2024, the vaccine Arexvy, which protects against the respiratory syncytial virus (RSV), developed by British pharmaceutical company GSK, was approved by the Health Sciences Authority (HSA).

Technological innovations, particularly in mRNA technology, are revolutionizing vaccine development, enabling rapid and effective responses to emerging respiratory threats. Additionally, increased public awareness and government initiatives to promote vaccination are contributing to the expansion of the respiratory disease vaccine market.

The overall Respiratory Disease Vaccine Industry is classified based on the technology, age group, infection, distribution channel, and region.

mRNA technology will play a pivotal role in the growth of the Respiratory Disease Vaccine Market. The success of mRNA vaccines in addressing COVID-19 has demonstrated their potential for rapid development and high efficacy. This technology enables the creation of vaccines that can be swiftly adapted to new strains of respiratory viruses, offering a flexible and timely response to emerging threats. mRNA vaccines work by instructing cells to produce a protein that triggers an immune response, providing protection against specific pathogens. The scalability, speed, and precision of mRNA technology will drive significant advancements in respiratory disease vaccines, meeting the growing demand for effective and adaptable solutions.

The pediatric segment will capture a notable share of the Respiratory Disease Vaccine Market. Vaccination programs targeting children are crucial for controlling the spread of respiratory diseases and protecting vulnerable populations. With the increasing focus on early childhood immunization and the rising prevalence of respiratory infections among children, there is a growing demand for vaccines specifically designed for this age group. Pediatric vaccines are being developed to address a range of respiratory conditions, including influenza and RSV, with an emphasis on safety, efficacy, and ease of administration. This segment's growth is driven by the need to safeguard children from severe respiratory illnesses and reduce the burden on healthcare systems.

Europe will experience substantial growth in the Respiratory Disease Vaccine Market from 2024 to 2032. The region benefits from a strong healthcare infrastructure, high vaccination rates, and a proactive approach to respiratory disease prevention. European countries are investing in advanced vaccine research and development, supported by robust regulatory frameworks and government initiatives. The emphasis on public health campaigns and vaccination programs is further driving market expansion. Additionally, Europe's diverse population and high prevalence of respiratory conditions create a significant demand for innovative vaccine solutions, contributing to the overall growth of the market in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory diseases
    • 3.2.1.2 Rising burden of diseases such as influenza, pneumonia, pertussis, and respiratory syncytial virus (RSV)
    • 3.2.1.3 Rising technological advancements
    • 3.2.1.4 Growing healthcare expenditure
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Complexity of developing vaccines due to evolving pathogens, increased expenses, and extended development times
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends
• 3.9 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Viral vector
• 5.3 mRNA
• 5.4 Conjugate
• 5.5 Live attenuated
• 5.6 Inactivated
• 5.7 Recombinant
• 5.8 Other technologies

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pediatric
• 6.3 Adult

Chapter 7 Market Estimates and Forecast, By Infection, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 COVID-19
• 7.3 Influenza
• 7.4 Respiratory syncytial virus (RSV)
• 7.5 Pneumonia
• 7.6 Other infections

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AstraZeneca
• 10.2 Emergent BioSolutions Inc.
• 10.3 GSK plc.
• 10.4 Johnson and Johnson Services, Inc.
• 10.5 Merck and Co., Inc.
• 10.6 Novavax
• 10.7 Pfizer Inc.
• 10.8 Sanofi SA
• 10.9 Serum Institute of India Pvt. Ltd.
• 10.10 SINOVAC